Pulmatrix, Inc. (PULM) |
| 1.23 0.02 (1.65%) 04-14 15:47 |
| Open: | 1.25 |
| High: | 1.3 |
| Low: | 1.22 |
| Volume: | 11,348 |
| Market Cap: | 4(M) |
| PE Ratio: | -0.87 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 2.49 |
| Resistance 1: | 1.98 |
| Pivot price: | 1.40 |
| Support 1: | 1.16 |
| Support 2: | 0.97 |
| 52w High: | 9.37 |
| 52w Low: | 1.16 |
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
| EPS | -1.410 |
| Book Value | 1.040 |
| PEG Ratio | 0.00 |
| Gross Profit | -0.010 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -45.9 |
| Return on Equity (ttm) | -80.9 |
Mon, 13 Apr 2026
PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders - Bluefield Daily Telegraph
Mon, 13 Apr 2026
PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
Sat, 11 Apr 2026
If You Invested $1,000 in Pulmatrix (PULM) - Stock Titan
Thu, 26 Mar 2026
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan - PR Newswire
Mon, 02 Mar 2026
CSRC delays leave Pulmatrix merger dead, company hunts new deal - Stock Titan
Mon, 02 Mar 2026
Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead - Stocktwits
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |